No abstract

Coronavirus disease 2019 is a severe acute respiratory syndrome, and wearing a mask is an important preventive measure. However, long-term use can cause “maskne,” or mask-induced acne. This study evaluated the prevalence, clinical characteristics, and severity of mask-induced acne and its effect on pre-existing dermatosis using an online questionnaire. The questionnaire comprised 15 questions on six primary topics: demographic data, type of face mask, dermatological symptoms after using a mask, preexisting dermatological conditions, the duration of use, and the effects of mask use on existing dermatological conditions. We included 1,025 participants; 48.6 % had dermatological symptoms after using masks. The most common symptoms were red papules (33.8 %) and itching (27.2 %). Individuals who wore masks for more than four hours daily experienced more dermatological symptoms, for example, healthcare providers, who had a higher risk of mask-related dermatosis than participants with other occupations. Moreover, masks significantly increased the severity of rosacea, contact dermatitis, and seborrheic dermatitis. These results suggest that board-certified dermatologists should assess patients in larger-scale studies to determine adequate management strategies.

Background Striae distensae (SD) or stretch marks are a common dermatological condition where the dermis becomes scarred. This phenomenon is associated with many risk factors. This study aimed to evaluate the clinical variables and risk factors in patients with SD in Riyadh, Kingdom of Saudi Arabia (KSA). Methods A cross-sectional study was conducted to assess the clinical variables and risk factors for stretch marks among adults in Riyadh, KSA. An electronic questionnaire with an informed consent section was distributed randomly to a sample of adult patients in Riyadh city, KSA, from April to June 2021. A sample size of 512 participants was calculated using the Cochran formula (n = Z2pq/e2), considering 95% confidence and precision of at least ±5%. A 95% confidence level yielded Z values of 1.96, per the normal tables. Results A total of 512 participants were included in this study. This study found that 41.4% of the participants were aged 15 to 25 years of which, 70.4% of the participants were females, and 38.2% had a body mass index (BMI) of 24 or more. More than half of the participants (54.0%) indicated white skin color. The most prevalent area of striae, as reported by the participants, was the abdomen (57%). Around 19.1% of the participants with stretch marks stated that they were smokers, and 23.9% stated that they were obese o, had a chronic condition such as hypertension or diabetes mellitus. The majority of the participants (70.5%) had a family history of stretch marks. Conclusions This study showed that the prevalence of stretch marks was higher in females, younger participants, smokers, participants with a family history of stretch marks, and participants with a higher BMI and multiparity. More studies should be conducted to assess the correlations between these factors and the presence of stretch marks, and their influence on the quality of life of individuals.

The coronavirus vaccine was developed to help overcome the COVID‐19 crisis. This study aimed to identify the cutaneous side effects secondary to Pfizer‐BioNTech and Oxford‐AstraZeneca COVID‐19 vaccines in the general population of Saudi Arabia and to list the risk factors for the development of cutaneous side effects. This cross‐sectional study was conducted in 2021, self‐administered surveys were distributed electronically through social media, and telephonic interviews were conducted with a sample size of 1000 participants. Data analysis was performed using Statistical Package for the Social Sciences. A total of 1021 patients (229 male and 722 female) aged 12 years or older were included. While 833 participants were medically free, 188 had chronic illnesses. While 802 participants were not taking any medications, 219 were taking medications regularly. Oxford‐Astra Zeneca and Pfizer BioNTech vaccines were administered to 319 and 702 participants, respectively. One‐hundred and twenty‐five participants previously had COVID‐19 infection and 407 were exposed to a PCR positive case of COVID. Six hundred and fifty‐nine patients (64.5%) reported experiencing injection site reactions: 606 (59.4%) had injection site pain, 168 (16.5%) had injection site swelling, and 107 (10.5%) had injection site redness. Only 51 patients (5%) experienced cutaneous side effects after injection. A significant association was found between chronic illnesses and cutaneous side effects post‐vaccine (9% vs. 4.1%; p value = 0.005). Patients on medications showed a higher rate of symptoms (8.2% vs. 4.1%; p value = 0.005). Age, gender, vaccine types, and history of COVID‐19 infection were not significantly associated with cutaneous side effects post‐vaccine.

BackgroundMicrofocused ultrasound with visualization (MFU‐V) delivers focused ultrasound energy to heat tissue and has emerged as a fast and effective noninvasive method for treating skin laxity. After obtaining approval in 2009 by the Food and Drug Administration, satisfactory feedback was recorded using several scoring systems for MFU‐V treatment for facial and neck laxity.AimTo evaluate the efficacy and satisfaction rates of MFU‐V for facial and neck laxity treatment by providing a basis for developing a validated scoring system for MFU‐V treatment.MethodA constrictive survey was carried out by selecting relevant publications on MFU‐V treatment of facial and neck laxity using PubMed, Medline, and Embase electronic databases from January 2017 to March 2022.ResultsOf the 11 original articles used in this review, the majority of the scoring methods used were the subjective global aesthetic improvement scale and the 5‐point scale rating global aesthetic improvement in appearance. Around half of the patients were described as much improved or very much improved on days 30 and 90, while most returned to baseline on Day 360. Most of the adverse events reported were mild bruising, redness, and pain. None of the patients reported serious adverse events. A burn occurred in one case because of improper application of the probe.ConclusionThe MFU‐V provides excellent and promising responses for treating facial and neck laxity. A few mild events were observed, such as erythema, pain, edema, and injection‐site induration, all of which resolved within approximately 2–3 days.